Methadone: Maximizing Safety and Efficacy for Pain Control in Patients with Cancer

Hematol Oncol Clin North Am. 2018 Jun;32(3):405-415. doi: 10.1016/j.hoc.2018.01.004. Epub 2018 Mar 22.

Abstract

Methadone is a valuable opioid in the management of patients who have cancer with pain. Methadone is a mu-, kappa-, and delta-opioid agonist, and an N-methyl-D-aspartate receptor antagonist. These mechanisms of action make methadone an attractive option for complex pain syndromes. It is critically important that providers consider a patient's risk status before beginning methadone. Careful consideration must be given to dosing methadone in both opioid-naïve and opioid-tolerant patients, with vigilant monitoring for therapeutic effectiveness and potential toxicity until the patient achieves steady state.

Keywords: Analgesics; Cancer pain; Methadone; Opioid; Pain management.

Publication types

  • Review

MeSH terms

  • Half-Life
  • Humans
  • Inappropriate Prescribing / mortality
  • Methadone* / adverse effects
  • Methadone* / pharmacokinetics
  • Methadone* / therapeutic use
  • Neoplasms / drug therapy
  • Neoplasms / mortality
  • Pain* / drug therapy
  • Pain* / mortality
  • Pain* / physiopathology

Substances

  • Methadone